Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2–negative metastatic breast cancer

AF Schott, LJ Goldstein, M Cristofanilli, PA Ruffini… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor
selectively expressed by breast cancer stem cells (BCSCs). Reparixin is an investigational …
被引用次数：200 相关文章

Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2–negative metastatic breast cancer

AF Schott, LJ Goldstein… - Clinical Cancer …, 2017 - scholars.northwestern.edu
Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor
selectively expressed by breast cancer stem cells (BCSCs). Reparixin is an investigational …

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.

AF Schott, LJ Goldstein, M Cristofanilli… - … Cancer Research: an …, 2017 - europepmc.org
Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor
selectively expressed by breast cancer stem cells (BCSCs). Reparixin is an investigational …

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

AF Schott, LJ Goldstein, M Cristofanilli… - Clinical Cancer …, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: Chemokine receptor 1 (CXCR1) is
recognized as an actionable receptor selectively expressed by breast cancer stem cells …

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer

AF Schott, LJ Goldstein… - … : an official journal …, 2017 - pubmed.ncbi.nlm.nih.gov
Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor
selectively expressed by breast cancer stem cells (BCSCs). Reparixin is an investigational …
[PDF] researchgate.net

[PDF][PDF] Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

AF Schott, LJ Goldstein, M Cristofanilli, PA Ruffini… - Clin Cancer …, 2017 - researchgate.net
Abstract Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor
selectively expressed by breast cancer stem cells (BCSCs). Reparixin is an investigational …
[HTML] nih.gov

[HTML][HTML] Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC)

AF Schott, LJ Goldstein, M Cristofanilli… - … cancer research: an …, 2017 - ncbi.nlm.nih.gov
Background CXCR1 is recognized as an actionable receptor selectively expressed by
breast cancer stem cells (BCSC). Reparixin is an investigational allosteric inhibitor of …